Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Qiagen ( (QGEN) ).
QIAGEN N.V. has been informed by the Netherlands Authority For the Financial Markets (AFM) about a notification concerning its voting rights, involving significant holdings by Goldman Sachs Group Inc. The notification details various types of shares and financial instruments held by Goldman Sachs, indicating both real and potential voting rights. This announcement reflects the intricate financial maneuvers and significant stake Goldman Sachs holds in QIAGEN, potentially impacting the company’s governance and market perception.
The most recent analyst rating on (QGEN) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, focusing on the development and distribution of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is listed on multiple stock exchanges including Frankfurt, NYSE, and SIX.
Average Trading Volume: 1,172,126
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.88B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.